Literature DB >> 11506737

Interleukin-12 p40/p70 ratio and in vivo responsiveness to IFN-alpha treatment in chronic hepatitis C.

G Piazzolla1, C Tortorella, G Fiore, M Fanelli, A Pisconti, S Antonaci.   

Abstract

To evaluate the relationship between cytokine balance and responsiveness to interferon-alpha (IFN-alpha), we investigated the production of IFN-gamma, interleukin-10 (IL-10), IL-12 p70, and IL-12 p40 by peripheral blood mononuclear cell (PBMC) cultures from patients with chronic hepatitis C (CHC) before and after 1 year of IFN-alpha treatment. Before the therapy, responder (R) patients exhibited lower IFN-gamma release, higher IL-10 production, and higher values of the IL12 p40/p70 ratio compared with nonresponders (NR). Increased sensitivity to the effects of IL-12 and IL-10, as well as higher IL-12-dependent IFN-gamma secretion, were also found in the R subset. After IFN-alpha therapy, an increase in IFN-gamma production and a decrease in the IL-12 p40/p70 ratio were observed in R patients, whereas opposite results were obtained in the NR group. Finally, the therapy induced downregulation of IL-10 production and cell responsiveness to recombinant IL-12 in all patients. These findings imply that predominance of a T helper 2 (Th2) cytokine profile in CHC patients favors the beneficial effects of IFN-alpha, thus suggesting a therapeutic role for Th1-driven stimulation of immune response. The findings also stress the primary importance of the IL-12 p40 and p70 balance in the modulation of immune responses to hepatitis C virus (HCV).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11506737     DOI: 10.1089/10799900152434303

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  6 in total

1.  Kinetics of soluble tumour necrosis factor (TNF)-alpha receptors and cytokines in the early phase of treatment for chronic hepatitis C: comparison between interferon (IFN)-alpha alone, IFN-alpha plus amantadine or plus ribavirin.

Authors:  F Torre; S Rossol; N Pelli; M Basso; A Delfino; A Picciotto
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

2.  Effects of interferon-alpha subtypes on the TH1/TH2 balance in peripheral blood mononuclear cells from patients with hepatitis virus infection-associated liver disorders.

Authors:  Toshio Ariyasu; Takeshi Tanaka; Noboru Fujioka; Yoshiaki Yanai; Shigeto Yamamoto; Hiroshi Yamauchi; Hakuo Ikegami; Masao Ikeda; Masashi Kurimoto
Journal:  In Vitro Cell Dev Biol Anim       Date:  2005 Jan-Feb       Impact factor: 2.416

3.  Immunogenic properties of a chimeric plant virus expressing a hepatitis C virus (HCV)-derived epitope: new prospects for an HCV vaccine.

Authors:  G Piazzolla; M Nuzzaci; C Tortorella; E Panella; A Natilla; D Boscia; A De Stradis; P Piazzolla; S Antonaci
Journal:  J Clin Immunol       Date:  2005-03       Impact factor: 8.317

4.  Differential IL-12 signaling induces human natural killer cell activating receptor-mediated ligand-specific expansion.

Authors:  Avishai Shemesh; Harry Pickering; Kole T Roybal; Lewis L Lanier
Journal:  J Exp Med       Date:  2022-06-27       Impact factor: 17.579

5.  Improvement of steatosis after interferon therapy in HCV genotype 4 is related to weight loss.

Authors:  G Esmat; Wafaa El Akel; M Metwally; A Soliman; W Doss; M Abdel Hamid; M Kamal; K Zalata; H Khattab; M El-Kassas; M Esmat; A Hasan; M El-Raziky
Journal:  Indian J Gastroenterol       Date:  2009-08-21

6.  The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C.

Authors:  Hermann E Wasmuth; Christian Stolte; Andreas Geier; Christoph G Dietrich; Carsten Gartung; Johann Lorenzen; Siegfried Matern; Frank Lammert
Journal:  BMC Infect Dis       Date:  2004-02-13       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.